Article · 19 Jun 2026
Conference abstract
Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/ FVIII concentrate (VONCENTO) in subjects with haemophilia A (SWIFT-HA study)
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: VONCENTO (CSL Behring) is a plasma-derived, high-concentration, low-volume, high-purity concentrate, which contains a high level of von Willebrand factor (VWF) high-molecular-weight multimers and a VWF/factor VIII (FVIII) ratio of -2.4:1, similar to Haemate P (CSL Behring). Methods: The pharmacokinetic, efficacy and safety profiles of VONCENTO were investigated in this multicentre double-blind, randomised study. Subjects aged _>12 years with haemophilia A who required treatment of non-surgical bleeds, treatment during surgical events or who were receiving prophylaxis were included. Pharmacokinetics were investigated with a single dose of 50 IU) FVIII/kg body weight of either VONCENTO or BIOSTATE reference product (Biostate-RP) (Day 1: Day 8 (n = 16), repeated on Day 180 [VONCENTO only; n = 15J).Efficacy and safety analyses were performed either during on-demand treatment (n = 52) or prophylaxis (n = 29)for â?¥6 months and â?¥50 exposure days, respectively. Results: Besides the confirmation of bioequivalence between VONCENTO and Biostate-RP, which displayed comparable PK profiles, haemostatic efficacy was rated by the investigators as either "excellent" or " good" in 96.4% of all bleeding events (96.5% spontaneous, 96.6% traumatic. 96.9% joint bleeds) as well as in 80% of major and 100% of minor surgical procedures at discharge. The median number of annualised bleeding events per subject (range) was significantly lower in the prophylaxis group (2.0 (0.0-34.6)) than in the on-demand group (14.0 (0.0-87.8), p = 0.0013).VONCENTO was well tolerated and no inhibitory antibodies were identified during the study period. Conclusions: : This study demonstrated the bioequivalence of VONCENTO to Biostate-RP, and its excellent efficacy and safety profile in haemophilia A subjects.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmacovigilance.
Article · 19 Jun 2026
Strengthening Healthcare Outcomes Through Effective Drug Safety Practices
Article · 19 Jun 2026
Expanding Patient Care Through Clinical Pharmacy Services in Modern Healthcare
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacovigilance
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Aleksander Skotnick”
